An open randomized study in 97 women with culture-confirmed symptomatic vaginal candidosis was performed to compare the efficacy and acceptability of single-dose treatment with terconazole 240 mg vaginal suppositories to that of clotrimazole 500 mg vaginal tablets. At patient review 7 days after treatment, primary treatment success defined by negative vaginal culture for yeasts with symptomatic improvement was observed in 87% of the terconazole group and 90% of the clotrimazole group. Only 3% of the terconazole group and 6% of the clotrimazole group remained both symptomatic and culture-positive for yeasts. At the final review 28 days after treatment, 70% of the terconazole group and 81% of the clotrimazole group remained culture-negative. Symptomatic culture-positive relapse/reinfection occurred in 17% of the terconazole-treated women and 12% of the clotrimazole-treated women. The remaining patients in either group had asymptomatic vaginal recolonization with yeasts. There were no significant differences between the groups in terms of their symptomatic and clinical responses or in their mycologically determined response to treatment. Both terconazole 240 mg vaginal suppositories and clotrimazole 500 mg vaginal tablets were well tolerated and equally effective in the single-dose treatment of vaginal candidosis.

Keywords:
Clotrimazole, Terconazole, Vaginal candidosis
This content is only available via PDF.
© 1985 S. Karger AG, Basel
1985
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.